Oncolytics Biotech, Inc. (TSE:ONC) had its Buy rating reiterated by Royal Bank of Canada with a C$10.00 price target

Analyst Ratings For Oncolytics Biotech, Inc. (TSE:ONC)

Story continues below

Today, Royal Bank of Canada reiterated its Buy rating on Oncolytics Biotech, Inc. (TSE:ONC) with a price target of C$10.00.

There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Oncolytics Biotech, Inc. (TSE:ONC) is Buy with a consensus target price of C$10.00 per share, a potential 292.16% upside.

Some recent analyst ratings include

  • 3/12/2019-Oncolytics Biotech, Inc. (TSE:ONC) had its Buy rating reiterated by Royal Bank of Canada with a C$10.00 price target

    Recent Trading Activity for Oncolytics Biotech, Inc. (TSE:ONC)
    Shares of Oncolytics Biotech, Inc. closed the previous trading session at 2,55 −0,14 5,20 % with shares trading hands.

    An ad to help with our costs